SCHEMBL20944675

SCHEMBL20944675

N/C(=N\O)c1cc(OC(F)F)cc(C(=O)O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX4 Q96LA9 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ GFER P55789 2/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ ADAM17 P78536 1/20 0.35
▸ MAPT P10636 3/20 0.34
▸ ATM Q13315 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KMT2A Q03164 4/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ SENP8 Q96LD8 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33
▸ SENP6 Q9GZR1 1/20 0.33
▸ TAS2R14 Q9NYV8 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ GRM2 Q14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20944678 1.00 MRGPRX4 (0.39) MRGPRX4KDM4EL3MBTL1GFERALOX15
SCHEMBL27893362 0.85 MRGPRX4 (0.47) MRGPRX4KDM4EGFERALOX15ADAM17
SCHEMBL20944029 0.84 KMT2A (0.49) KDM4EKMT2AMEN1ALDH1A1F2
SCHEMBL20944031 0.84 KMT2A (0.49) KDM4EKMT2AMEN1ALDH1A1F2
SCHEMBL29278604 0.84 POLB (0.41) KDM4EL3MBTL1GFERALOX15ADAM17
SCHEMBL20963803 0.84 POLB (0.41) KDM4EL3MBTL1GFERALOX15ADAM17
SCHEMBL30745102 0.84 POLB (0.41) KDM4EL3MBTL1GFERALOX15ADAM17
SCHEMBL4235825 0.81 MRGPRX4 (0.47) MRGPRX4KDM4EGFERALOX15ADAM17
SCHEMBL14738759 0.79 RXRA (0.45) KDM4EMAPTATMRAB9ALMNA
SCHEMBL14738760 0.79 RXRA (0.45) KDM4EMAPTATMRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10730863-B2 Bridged bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-04 — — US disclosed
CN-111295382-A Bridged bicyclic compounds as modulators of farnesoid X receptors 百时美施贵宝公司 2020-06-16 — — CN disclosed
US-20190127358-A1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2019-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127358-A1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS NR1H4, FXR1, NR1H2 MRGPRX4 440/4885KDM4E 3658/4885L3MBTL1 4007/4885
US-10730863-B2 Bridged bicyclic compounds as farnesoid X receptor modulators NR1H4, FXR1, NR1H2 MRGPRX4 440/4885KDM4E 3658/4885L3MBTL1 4007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback